Issues to debate on the Women's Health Initiative: estrogen: an instrument or the conductor of the orchestra?

Although it is well known that cyclic production of sex hormones is essential to establish reproductive function and female characteristics, distant impacts of the activity of the female endocrine system result from a concert of delicate mechanisms. Estrogen is rather an instrument than a conductor in this physiological orchestra of the female. Thus, controversies in the explanation of results from studies on hormone replacement therapy (HRT) and cardiovascular disease (CVD) prevention might be eliminated, if we analyse not only the role of estrogen but a broader spectrum of factors leading to CVD. Authors would like to hypothesize that haemorheological changes in women around menopause, such as increased blood and plasma viscosity, haematocrit and fibrinogen, are largely responsible for the increased mortality in the post-menopausal life period. We believe that a cyclic withdrawal bleeding establishes a more favourable haemorheological condition, thus, sequentially administered estrogen might be protective in post-menopausal women. Nevertheless, other factors, that decrease blood viscosity, such as daily exercise, intake of ample amount of fluids as well as ideal nutrition, are equally important. We are confident that sequential HRT, as well as healthy life style and risk prevention programmes have their proper place in the management of this issue.

[1]  Daniel L. McGee,et al.  Hematocrit and the risk of coronary heart disease: the Honolulu Heart Program. , 1983, American heart journal.

[2]  A. Sherwood,et al.  Changes in hemodynamics and left ventricular structure after menopause. , 2002, The American journal of cardiology.

[3]  V. Beral,et al.  Evidence from randomised trials on the long-term effects of hormone replacement therapy , 2002, The Lancet.

[4]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[5]  H. Tunstall-Pedoe Myth and paradox of coronary risk and the menopause , 1998, The Lancet.

[6]  P. Burge,et al.  MORBIDITY AND MORTALITY IN PSEUDOPOLYCYTHÆMIA , 1975, The Lancet.

[7]  M. Woodward,et al.  Associations of blood rheology and interleukin‐6 with cardiovascular risk factors and prevalent cardiovascular disease , 1999, British journal of haematology.

[8]  Fröhlich,et al.  Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women , 1998, British journal of haematology.

[9]  D. Barlow Time to reflect on the Women's Health Initiative (WHI) study. , 2003, Human reproduction.

[10]  N. Milman,et al.  Haemoglobin concentrations appear to be lower in indigenous Greenlanders than in Danes: assessment of haemoglobin in 234 Greenlanders and in 2804 Danes , 2001, European journal of haematology.

[11]  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991 .

[12]  P. Allhoff,et al.  The Stockholm Prospective Study , 1991 .

[13]  P. Sorlie,et al.  Hematocrit and risk of coronary heart disease: the Puerto Rico Heart Health Program , 1981 .

[14]  J. Bigger,et al.  Observations on blood viscosity changes after acute myocardial infarction. , 1975, Circulation.

[15]  G. M. Goni,et al.  Effect of hormone replacement therapy upon haemorheological variables. , 2003, Clinical hemorheology and microcirculation.